FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / New insights in the diagnosis and treatment of equine piropl...
Frontiers in veterinary science2024; 11; 1459989; doi: 10.3389/fvets.2024.1459989

New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths.

Abstract: Equine piroplasmosis (EP) is a global tick-borne disease of equids caused by the intraerythrocytic apicomplexan parasites and , and the more recently discovered . These parasites can be transmitted by several tick species, including , , and , but iatrogenic and vertical transmission are also common. Clinical signs of EP include poor performance, fever, icterus, abortions, among others, and peracute or acute forms of infection are associated with high mortality in non-endemic areas. EP is a reportable disease and represents an important barrier for the international trade of horses and other equids, causing disruption of international equine sports. Tick control measures, serological and molecular diagnostic methods, and parasiticidal drugs are currently used against EP, while vaccines remain unavailable. Since most acaricides used in equids are non-environmentally friendly and linked to drug resistances, this is considered as an unsustainable approach. Imidocarb dipropionate (ID) and buparvaquone (BPQ) are currently the main drugs used to control the disease. However, while ID has several side and toxic effects and recurrent failures of treatment have been reported, BPQ is less effective in the clearance of infection and not available in some countries. Thus, novel alternative and effective therapeutics are needed. While current trade regulations require testing equids for EP before exportation, the lack of standardized PCR tests and limitations of the currently recommended serological assays entail a risk of inaccurate diagnosis. Hereby, we propose a combination of standardized PCR-based techniques and improved serological tests to diminish the risks of exporting EP-infected animals making equid international trade safer. In addition, this review discusses, based on scientific evidence, several idiosyncrasies, pitfalls and myths associated with EP, and identifies weaknesses of current methods of control and gaps of research, as initial steps toward developing novel strategies leading to control this disease.
Copyright © 2024 Mendoza, Pérez-Écija, Kappmeyer, Suarez and Bastos.
Get Full Text
Publication Date: 2024-08-14 PubMed ID: 39205808PubMed Central: PMC11349644DOI: 10.3389/fvets.2024.1459989Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research looks at equine piroplasmosis, a global disease affecting horses and similar species, which poses barriers to international trade of these animals. The researchers discuss diagnostic methods, current treatments and control methods, including the inadequacies of these approaches.

Understanding Equine Piroplasmosis

  • The disease, equine piroplasmosis (EP), affects equids (a family of animals which includes horses, donkeys, and zebras). It’s caused by parasites and can be passed on by multiple tick species. However, aside from tick transmission, the disease can also be spread iatrogenically (through medical procedures) and from mother to offspring (vertical transmission).
  • EP results in multiple clinical signs such as poor performance, fever, jaundice, and miscarriages. Particularly severe or sudden forms of the infection have a high death rate in areas where the disease isn’t commonly found.
  • Because of its severity and wide-spread nature, EP is a reportable disease and it has significant effects on international trade of equids. Essentially, EP disrupts equine sports globally.

Current Measures Against Equine Piroplasmosis and Their Limitations

  • Tick control measures, serological and molecular diagnostic methods, and drugs against parasites are all used to combat EP. However, no vaccines are currently available.
  • Acaricides, intended for tick control in equids, are often harmful to the environment and have been linked to the development of drug resistances, making them an unsustainable solution.
  • Imidocarb dipropionate (ID) and buparvaquone (BPQ) are the main drugs used to treat the disease currently. Yet, these are fraught with their own problems. ID has numerous side effects and treatment failures have been reported recurrently. BPQ, on the other hand, isn’t very effective against one of the parasites causing EP and isn’t available in all countries. This pushes the need for the development of alternative and effective treatments.

Limitations in Diagnostics and Suggestions for Improvement

  • Current regulations necessitate the testing of equids for EP before they can be exported. But, the lack of standardization in PCR tests and limitations of serological assays that are recommended now risk inaccurate diagnoses. Therefore, the authors suggest the use of standardized PCR techniques and improved serological tests to decrease the risk of exporting infected animals and to enhance the safety of international trade.
  • The researchers provide a review of several particular characteristics, pitfalls and misconceptions associated with EP, also bringing attention to the shortcomings of existing control methods and the gaps in the research field.
  • Through this identification of limitations and gaps, the authors aim to pave the way for the development of novel strategies to control this disease.

Cite This Article

APA
Mendoza FJ, Pérez-Écija A, Kappmeyer LS, Suarez CE, Bastos RG. (2024). New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths. Front Vet Sci, 11, 1459989. https://doi.org/10.3389/fvets.2024.1459989

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 11
Pages: 1459989
PII: 1459989

Researcher Affiliations

Mendoza, Francisco J
  • Department of Animal Medicine and Surgery, College of Veterinary Medicine, University of Cordoba, Cordoba, Spain.
Pérez-Écija, Alejandro
  • Department of Animal Medicine and Surgery, College of Veterinary Medicine, University of Cordoba, Cordoba, Spain.
Kappmeyer, Lowell S
  • Animal Disease Research Unit, Agricultural Research Service, United States Department of Agriculture (USDA), Pullman, WA, United States.
Suarez, Carlos E
  • Animal Disease Research Unit, Agricultural Research Service, United States Department of Agriculture (USDA), Pullman, WA, United States.
  • Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.
Bastos, Reginaldo G
  • Animal Disease Research Unit, Agricultural Research Service, United States Department of Agriculture (USDA), Pullman, WA, United States.
  • Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

This article includes 112 references
  1. Tirosh-Levy S, Gottlieb Y, Fry LM, Knowles DP, Steinman A. Twenty years of equine piroplasmosis research: global distribution, molecular diagnosis, and phylogeny.. Pathogens (2020) 9:926.
    doi: 10.3390/pathogens9110926pmc: PMC7695325pubmed: 33171698google scholar: lookup
  2. Knowles DP, Kappmeyer LS, Haney D, Herndon DR, Fry LM, Munro JB. Discovery of a novel species, Theileria haneyi n. sp., infective to equids, highlights exceptional genomic diversity within the genus Theileria: implications for apicomplexan parasite surveillance.. Int J Parasitol (2018) 48:679–90.
    doi: 10.1016/j.ijpara.2018.03.010pubmed: 29885436google scholar: lookup
  3. Kumar S, Kumar R, Sugimoto C. A perspective on Theileria equi infections in donkeys.. Jpn J Vet Res (2009) 56:171–80.
    doi: 10.14943/jjvr.56.4.171pubmed: 19358444google scholar: lookup
  4. Onyiche TE, Taioe MO, Molefe NI, Biu AA, Luka J, Omeh IJ. Equine piroplasmosis: an insight into global exposure of equids from 1990 to 2019 by systematic review and meta-analysis.. Parasitology (2020) 147:1411–24.
    doi: 10.1017/S0031182020001407pmc: PMC10317785pubmed: 32741382google scholar: lookup
  5. Qablan MA, Sloboda M, Jirků M, Oborník M, Dwairi S, Amr ZS. Quest for the piroplasms in camels: identification of Theileria equi and Babesia caballi in Jordanian dromedaries by PCR.. Vet Parasitol (2012) 186:456–60.
    doi: 10.1016/j.vetpar.2011.11.070pubmed: 22186193google scholar: lookup
  6. Da Silveira AW, De Oliveira GG, Menezes Santos L, da Silva Azuaga LB, Macedo Coutinho CR, Echeverria JT. Natural infection of the South American tapir (Tapirus terrestris) by Theileria equi.. J Wildl Dis (2017) 53:411–3.
    doi: 10.7589/2016-06-149pubmed: 28151085google scholar: lookup
  7. Hegab AA, Fahmy MM, Omar HM, Ghattas SG, Mahmoud NE, Abuowarda M. Occurrence and genotyping of Theileria equi in dogs and associated ticks in Egypt.. Med Vet Entomol (2023) 37:252–62.
    doi: 10.1111/mve.12627pubmed: 36444709google scholar: lookup
  8. Rothschild CM. Equine piroplasmosis.. J Equine Vet (2013) 33:497–508.
    doi: 10.1016/j.jevs.2013.03.189google scholar: lookup
  9. Tamzali Y. Equine piroplasmosis: an updated review.. Equine Vet Educ (2013) 25:590–8.
    doi: 10.1111/eve.12070google scholar: lookup
  10. Scoles GA, Ueti MW. Vector ecology of equine piroplasmosis.. Annu Rev Entomol (2015) 60:561–80.
    doi: 10.1146/annurev-ento-010814-021110pubmed: 25564746google scholar: lookup
  11. Almazán C, Scimeca RC, Reichard MV, Mosqueda J. Babesiosis and theileriosis in North America.. Pathogens (2022) 11:168.
    doi: 10.3390/pathogens11020168pmc: PMC8874406pubmed: 35215111google scholar: lookup
  12. Graham H, van Kalsbeek P, van der Goot J, Koene MGJ. Low seroprevalence of equine piroplasmosis in horses exported from the Netherlands between 2015 and 2021.. Front Vet Sci (2022) 9:954046.
    doi: 10.3389/fvets.2022.954046pmc: PMC9588945pubmed: 36299627google scholar: lookup
  13. Joachim A, Cavalleri JV, Berger S. Equine anaplasmosis and equine piroplasmosis in Germany, Austria and Switzerland - previously anecdotal, now relevant?. Schweiz Arch Tierheilkd (2022) 164:35–50.
    doi: 10.17236/sat00335pubmed: 34983738google scholar: lookup
  14. Nadal C, Bonnet SI, Marsot M. Eco-epidemiology of equine piroplasmosis and its associated tick vectors in Europe: a systematic literature review and a meta-analysis of prevalence.. Transbound Emerg Dis (2022) 69:2474–98.
    doi: 10.1111/tbed.14261pubmed: 34333863google scholar: lookup
  15. Coultous RM, Sutton DGM, Boden LA. A risk assessment of equine piroplasmosis entry, exposure and consequences in the UK.. Equine Vet J (2023) 55:282–94.
    doi: 10.1111/evj.13579pmc: PMC10083907pubmed: 35478189google scholar: lookup
  16. Axt CW, Springer A, Strube C, Jung C, Naucke TJ, Müller E. Molecular and serological detection of vector-borne pathogens responsible for equine piroplasmosis in Europe between 2008 and 2021.. Microorganisms (2024) 12:816.
    doi: 10.3390/microorganisms12040816pmc: PMC11051957pubmed: 38674760google scholar: lookup
  17. Scoles GA, Hutcheson HJ, Schlater JL, Hennager SG, Pelzel AM, Knowles DP. Equine piroplasmosis associated with Amblyomma cajennense ticks, Texas, USA.. Emerg Infect Dis (2011) 17:1903–5.
    doi: 10.3201/eid1710.101182pmc: PMC3310643pubmed: 22000367google scholar: lookup
  18. Short MA, Clark CK, Harvey JW, Wenzlow N, Hawkins IK, Allred DR. Outbreak of equine piroplasmosis in Florida.. J Am Vet Med Assoc (2012) 240:588–95.
    doi: 10.2460/javma.240.5.588pubmed: 22332629google scholar: lookup
  19. Onyiche TE, Suganuma K, Igarashi I, Yokoyama N, Xuan X, Thekisoe O. A review on equine piroplasmosis: epidemiology, vector ecology, risk factors, host immunity, diagnosis and control.. Int J Environ Res Public Health (2019) 16:1736.
    doi: 10.3390/ijerph16101736pmc: PMC6572709pubmed: 31100920google scholar: lookup
  20. Camino E, Cruz-Lopez F, de Juan L, Dominguez L, Shiels B, Coultous RM. Phylogenetic analysis and geographical distribution of Theileria equi and Babesia caballi sequences from horses residing in Spain.. Ticks Tick Borne Dis (2020) 11:101521.
    doi: 10.1016/j.ttbdis.2020.101521pubmed: 32993941google scholar: lookup
  21. Bastos RG, Sears KP, Dinkel KD, Kappmeyer L, Ueti MW, Knowles DP. Development of an indirect Elisa to detect equine antibodies to Theileria haneyi.. Pathogens (2021) 10:270.
    doi: 10.3390/pathogens10030270pmc: PMC7997436pubmed: 33673478google scholar: lookup
  22. Wise LN, Kappmeyer LS, Mealey RH, Knowles DP. Review of equine piroplasmosis.. J Vet Intern Med (2013) 27:1334–46.
    doi: 10.1111/jvim.12168pubmed: 24033559google scholar: lookup
  23. Wise LN, Pelzel-McCluskey AM, Mealey RH, Knowles DP. Equine piroplasmosis.. Vet Clin North Am Equine Pract (2014) 30:677–93.
    doi: 10.1016/j.cveq.2014.08.008pubmed: 25300637google scholar: lookup
  24. Goodrich EL, Behling-Kelly E. Clinical pathology of donkeys and mules.. Vet Clin North Am Equine Pract (2019) 35:433–55.
    doi: 10.1016/j.cveq.2019.08.002pubmed: 31672198google scholar: lookup
  25. Piantedosi D, D'Alessio N, Di Loria A, Di Prisco F, Mariani U, Neola B. Seroprevalence and risk factors associated with Babesia caballi and Theileria equi infections in donkeys from Southern Italy.. Vet J (2014) 202:578–82.
    doi: 10.1016/j.tvjl.2014.09.025pubmed: 25457263google scholar: lookup
  26. Sears KP, Knowles DP, Fry LM. Clinical progression of Theileria haneyi in splenectomized horses reveals decreased virulence compared to Theileria equi.. Pathogens (2022) 11:254.
    doi: 10.3390/pathogens11020254pmc: PMC8879895pubmed: 35215197google scholar: lookup
  27. Mahmoud MS, El-Ezz NT, Abdel-Shafy S, Nassar SA, El Namaky AH, Khalil WK. Assessment of Theileria equi and Babesia caballi infections in equine populations in Egypt by molecular, serological and hematological approaches.. Parasit Vectors (2016) 9:260.
    doi: 10.1186/s13071-016-1539-9pmc: PMC4857240pubmed: 27146413google scholar: lookup
  28. Solano-Gallego L, Sainz Á, Roura X, Estrada-Peña A, Miró G. A review of canine Babesiosis: the European perspective.. Parasit Vectors (2016) 9:336.
    doi: 10.1186/s13071-016-1596-0pmc: PMC4902949pubmed: 27289223google scholar: lookup
  29. Zobba R, Ardu M, Niccolini S, Chessa B, Manna L, Cocco R. Clinical and laboratory findings in equine piroplasmosis.. J Equine Vet (2008) 28:301–8.
    doi: 10.1016/j.jevs.2008.03.005google scholar: lookup
  30. Nardini R, Cersini A, Bartolomé Del Pino LE, Manna G, Scarpulla M, Di Egidio A. Comparison of direct and indirect methods to maximise the detection of Babesia caballi and Theileria equi infections in central Southern Italy.. Ticks Tick Borne Dis (2022) 13:101939.
    doi: 10.1016/j.ttbdis.2022.101939pubmed: 35474261google scholar: lookup
  31. Tenter AM, Friedhoff KT. Serodiagnosis of experimental and natural Babesia equi and B. Caballi infections.. Vet Parasitol (1986) 20:49–61.
    doi: 10.1016/0304-4017(86)90092-0pubmed: 3518217google scholar: lookup
  32. Bartolomé Del Pino LE, Nardini R, Veneziano V, Iacoponi F, Cersini A, Autorino GL. Babesia caballi and Theileria equi infections in horses in central-Southern Italy: sero-molecular survey and associated risk factors.. Ticks Tick Borne Dis (2016) 7:462–9.
    doi: 10.1016/j.ttbdis.2016.01.011pubmed: 26847198google scholar: lookup
  33. Bhoora R, Quan M, Matjila PT, Zweygarth E, Guthrie AJ, Collins NE. Sequence heterogeneity in the Equi Merozoite antigen gene (EMA-1) of Theileria equi and development of an EMA-1-specific Taqman MGB assay for the detection of T. equi.. Vet Parasitol (2010) 172:33–45.
    doi: 10.1016/j.vetpar.2010.04.025pubmed: 20493635google scholar: lookup
  34. Bhoora R, Quan M, Zweygarth E, Guthrie AJ, Prinsloo SA, Collins NE. Sequence heterogeneity in the gene encoding the Rhoptry-associated Protein-1 (Rap-1) of Babesia caballi isolates from South Africa.. Vet Parasitol (2010) 169:279–88.
    doi: 10.1016/j.vetpar.2010.01.009pubmed: 20138703google scholar: lookup
  35. Coultous R, Gotić J, McCann M, Sutton D, Beck R, Shiels B. Novel Equi Merozoite antigen (EMA-1) gene heterogeneity in a geographically isolated Theileria equi population in Croatia.. Parasit Vectors (2022) 15:401.
    doi: 10.1186/s13071-022-05484-4pmc: PMC9623909pubmed: 36316753google scholar: lookup
  36. Asenzo G, Wilkowsky S, Barrandeguy M, Mesplet M, Benitez D, Florin-Christensen M. Development of an indirect Elisa for the diagnosis of equine piroplasmosis.. Ann N Y Acad Sci (2008) 1149:235–8.
    doi: 10.1196/annals.1428.029pubmed: 19120219google scholar: lookup
  37. Yang G, Zhou B, Chen K, Hu Z, Guo W, Wang X. Diagnostic performance of competitive Elisa and Western blot methods for the detection ofantibodies against Theileria equi and Babesia caballi.. Microorganisms (2022) 11:21.
    doi: 10.3390/microorganisms11010021pmc: PMC9862631pubmed: 36677312google scholar: lookup
  38. Awinda PO, Mealey RH, Williams LB, Conrad PA, Packham AE, Reif KE. Serum antibodies from a subset of horses positive for Babesia caballi by competitive enzyme-linked immunosorbent assay demonstrate a protein recognition pattern that is notconsistent with infection.. Clin Vaccine Immunol (2013) 20:1752–7.
    doi: 10.1128/cvi.00479-13pmc: PMC3837787pubmed: 24049108google scholar: lookup
  39. Yang G, Chen K, Guo W, Hu Z, Qi T, Liu D. Development of a test card based on colloidal gold immunochromatographic strips for rapid detection of antibodies against Theileria equi and Babesia caballi.. Microbiol Spectr (2022) 10:e0241121.
    doi: 10.1128/spectrum.02411-21pmc: PMC8865536pubmed: 35196786google scholar: lookup
  40. Jongejan F, Du C, Papadopoulos E, Blanda V, Di Bella S, Cannella V. Diagnostic performance of a rapid immunochromatographic test for the simultaneous detection of antibodies to Theileria equi and Babesia caballi in horses and donkeys.. Parasit Vectors (2024) 17:160.
    doi: 10.1186/s13071-024-06253-1pmc: PMC10979598pubmed: 38549117google scholar: lookup
  41. Nardini R, Bartolomé Del Pino LE, Cersini A, Manna G, Viola MR, Antognetti V. Comparison of PCR-based methods for the detection of Babesia caballi and Theileria equi in field samples collected in Central Italy.. Parasitol Res (2021) 120:2157–64.
    doi: 10.1007/s00436-021-07153-4pubmed: 33855619google scholar: lookup
  42. Montes Cortés MG, Fernández-García JL, Habela Martínez-Estéllez MÁ. A multinested PCR for detection of the equine piroplasmids Babesia caballi and Theileria equi.. Ticks Tick Borne Dis (2019) 10:305–13.
    doi: 10.1016/j.ttbdis.2018.11.008pubmed: 30472099google scholar: lookup
  43. Kumar B, Maharana BR, Thakre B, Brahmbhatt NN, Joseph JP. 18s rRNA gene-based piroplasmid PCR: an assay for rapid and precise molecular screening of Theileria and Babesia species in animals.. Acta Parasitol (2022) 67:1697–707.
    doi: 10.1007/s11686-022-00625-2pmc: PMC9523193pubmed: 36178614google scholar: lookup
  44. Ahedor B, Otgonsuren D, Zhyldyz A, Guswanto A, Ngigi NMM, Valinotti MFR. Development and evaluation of specific polymerase chain reaction assays for detecting Theileria equi genotypes.. Parasit Vectors (2023) 16:435.
    doi: 10.1186/s13071-023-06045-zpmc: PMC10675911pubmed: 38007442google scholar: lookup
  45. Schwint ON, Ueti MW, Palmer GH, Kappmeyer LS, Hines MT, Cordes RT. Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential.. Antimicrob Agents Chemother (2009) 53:4327–32.
    doi: 10.1128/aac.00404-09pmc: PMC2764191pubmed: 19620328google scholar: lookup
  46. Baptista C, Lopes MS, Tavares AC, Rojer H, Kappmeyer L, Mendonça D. Diagnosis of Theileria equi infections in horses in the Azores using celisa and nested PCR.. Ticks Tick Borne Dis (2013) 4:242–5.
    doi: 10.1016/j.ttbdis.2012.11.008pubmed: 23337492google scholar: lookup
  47. Bhoora R, Franssen L, Oosthuizen MC, Guthrie AJ, Zweygarth E, Penzhorn BL. Sequence heterogeneity in the 18s rRNA gene within Theileria equi and Babesia caballi from horses in South Africa.. Vet Parasitol (2009) 159:112–20.
    doi: 10.1016/j.vetpar.2008.10.004pubmed: 19019541google scholar: lookup
  48. Liu J, Yang J, Guan G, Liu A, Wang B, Luo J. Molecular detection and identification of piroplasms in sika deer (Cervus nippon) from Jilin Province, China.. Parasit Vectors (2016) 9:156.
    doi: 10.1186/s13071-016-1435-3pmc: PMC4794910pubmed: 26984286google scholar: lookup
  49. Mshelia PW, Kappmeyer L, Johnson WC, Kudi CA, Oluyinka OO, Balogun EO. Molecular detection of Theileria species and Babesia caballi from horses in Nigeria.. Parasitol Res (2020) 119:2955–63.
    doi: 10.1007/s00436-020-06797-ypmc: PMC7431391pubmed: 32647992google scholar: lookup
  50. Bhoora R, Quan M, Franssen L, Butler CM, van der Kolk JH, Guthrie AJ. Development and evaluation of real-time PCR assays for the quantitative detection of Babesia caballi and Theileria equi infections in horses from South Africa.. Vet Parasitol (2010) 168:201–11.
    doi: 10.1016/j.vetpar.2009.11.011pubmed: 20031328google scholar: lookup
  51. Heim A, Passos LM, Ribeiro MF, Costa-Júnior LM, Bastos CV, Cabral DD. Detection and molecular characterization of Babesia caballi and Theileria equi isolates from endemic areas of Brazil.. Parasitol Res (2007) 102:63–8.
    doi: 10.1007/s00436-007-0726-1pubmed: 17828553google scholar: lookup
  52. Bhoora RV, Pienaar R, Cornelius F, Josemans A, Matthee O, Marumo R. Multiplex hydrolysis-probe assay for the simultaneous detection of Theileria equi and Babesia caballi infections in equids.. Vet Parasitol (2018) 255:61–8.
    doi: 10.1016/j.vetpar.2018.03.022pubmed: 29773138google scholar: lookup
  53. Zhou B, Yang G, Hu Z, Chen K, Guo W, Wang X. Development of a real-time quantitative PCR based on a Taqman-MGB probe for the rapid detection of Theileria haneyi.. Microorganisms (2023) 11:2633.
    doi: 10.3390/microorganisms11112633pmc: PMC10673206pubmed: 38004645google scholar: lookup
  54. Hall CM, Busch JD, Scoles GA, Palma-Cagle KA, Ueti MW, Kappmeyer LS. Genetic characterization of Theileria equi infecting horses in North America: evidence for a limited source of U.S. introductions.. Parasit Vectors (2013) 6:35.
    doi: 10.1186/1756-3305-6-35pmc: PMC3606381pubmed: 23399005google scholar: lookup
  55. Bishop RP, Kappmeyer LS, Onzere CK, Odongo DO, Githaka N, Sears KP. Equid infective Theileria cluster in distinct 18s rRNA gene clades comprising multiple taxa with unusually broad mammalian host ranges.. Parasit Vectors (2020) 13:261.
    doi: 10.1186/s13071-020-04131-0pmc: PMC7236219pubmed: 32430015google scholar: lookup
  56. Elsawy BSM, Mahmoud MS, Suarez CE, Alzan HF. Impact of equine and camel piroplasmosis in Egypt: how much do we know about the current situation?. Pathogens (2023) 12:1318.
    doi: 10.3390/pathogens12111318pmc: PMC10675018pubmed: 38003783google scholar: lookup
  57. Bhoora RV, Collins NE, Schnittger L, Troskie C, Marumo R, Labuschagne K. Molecular genotyping and epidemiology of equine piroplasmids in South Africa.. Ticks Tick Borne Dis (2020) 11:101358.
    doi: 10.1016/j.ttbdis.2019.101358pubmed: 31870636google scholar: lookup
  58. Ribeiro IB, Câmara AC, Bittencourt MV, Marçola TG, Paludo GR, Soto-Blanco B. Detection of Theileria equi in spleen and blood of asymptomatic piroplasm carrier horses.. Acta Parasitol (2013) 58:218–22.
    doi: 10.2478/s11686-013-0127-9pubmed: 23666659google scholar: lookup
  59. Alhassan A, Thekisoe OM, Yokoyama N, Inoue N, Motloang MY, Mbati PA. Development of loop-mediated isothermal amplification (lamp) method for diagnosis of equine piroplasmosis.. Vet Parasitol (2007) 143:155–60.
    doi: 10.1016/j.vetpar.2006.08.014pubmed: 16973284google scholar: lookup
  60. Dorrego A, Camino E, Gago P, Buendia-Andres A, Acurio K, Gonzalez S. Haemato-biochemical characterization of equine piroplasmosis asymptomatic carriers and seropositive, real-time PCR negative horses.. Vet Parasitol (2023) 323:110046.
    doi: 10.1016/j.vetpar.2023.110046pubmed: 37826971google scholar: lookup
  61. Ueti MW, Mealey RH, Kappmeyer LS, White SN, Kumpula-McWhirter N, Pelzel AM. Re-emergence of the apicomplexan Theileria equi in the United States: elimination of persistent infection and transmission risk.. PLoS One (2012) 7:e44713.
    doi: 10.1371/journal.pone.0044713pmc: PMC3435266pubmed: 22970295google scholar: lookup
  62. Jaffer O, Abdishakur F, Hakimuddin F, Riya A, Wernery U, Schuster RK. A comparative study of serological tests and PCR for the diagnosis of equine piroplasmosis.. Parasitol Res (2010) 106:709–13.
    doi: 10.1007/s00436-009-1669-5pubmed: 19894063google scholar: lookup
  63. Grause JF, Ueti MW, Nelson JT, Knowles DP, Kappmeyer LS, Bunn TO. Efficacy of imidocarb dipropionate in eliminating Theileria equi from experimentally infected horses.. Vet J (2013) 196:541–6.
    doi: 10.1016/j.tvjl.2012.10.025pubmed: 23199699google scholar: lookup
  64. Cunha CW, McGuire TC, Kappmeyer LS, Hines SA, Lopez AM, Dellagostin OA. Development of specific immunoglobulin Ga (IgGa) and IgGb antibodies correlates with control of parasitemia in Babesia equiinfection.. Clin Vaccine Immunol (2006) 13:297–300.
    doi: 10.1128/cvi.13.2.297-300.2006pmc: PMC1391941pubmed: 16467341google scholar: lookup
  65. Knowles DP Jr, Kappmeyer LS, Stiller D, Hennager SG, Perryman LE. Antibody to a recombinant merozoite protein epitope identifies horses infected with Babesia equi.. J Clin Microbiol (1992) 30:3122–6.
    doi: 10.1128/jcm.30.12.3122-3126.1992pmc: PMC270599pubmed: 1280648google scholar: lookup
  66. Kappmeyer LS, Perryman LE, Hines SA, Baszler TV, Katz JB, Hennager SG. Detection of equine antibodies to Babesia caballi by recombinant B. caballi Rhoptry-associated protein 1 in a competitive-inhibition enzyme-linked immunosorbent assay.. J Clin Microbiol (1999) 37:2285–90.
    doi: 10.1128/jcm.37.7.2285-2290.1999pmc: PMC85139pubmed: 10364599google scholar: lookup
  67. Alanazi AD, Said AE, Morin-Adeline V, Alyousif MS, Slapeta J. Quantitative PCR detection of Theileria equi using laboratory workflows to detect asymptomatic persistently infected horses.. Vet Parasitol (2014) 206:138–45.
    doi: 10.1016/j.vetpar.2014.09.019pubmed: 25450724google scholar: lookup
  68. El-Sayed SAE, Rizk MA, Baghdadi HB, Ringo AE, Sambuu G, Nugraha AB. Development of a promising antigenic cocktail for the global detection of Babesia caballi in horse by ELISA.. PLoS One (2023) 18:e0284535.
    doi: 10.1371/journal.pone.0284535pmc: PMC10104287pubmed: 37058508google scholar: lookup
  69. Rapoport A, Aharonson-Raz K, Berlin D, Tal S, Gottlieb Y, Klement E. Molecular characterization of the Babesia caballi RAP-1 gene and epidemiological survey in horses in Israel.. Infect Genet Evol (2014) 23:115–20.
    doi: 10.1016/j.meegid.2014.01.033pubmed: 24524984google scholar: lookup
  70. Coultous RM, Phipps P, Dalley C, Lewis J, Hammond T-A, Shiels BR. Equine piroplasmosis status in the UK: an assessment of laboratory diagnostic submissions and techniques.. Vet Rec (2019) 184:95.
    doi: 10.1136/vr.104855pubmed: 30413675google scholar: lookup
  71. Aida H, Foreman JH, Ochi A, Takizawa Y, Yamanaka T. A case of equine piroplasmosis in the Tokyo 2020 Olympic games.. J Equine Sci (2023) 34:93–9.
    doi: 10.1294/jes.32.93pmc: PMC10534063pubmed: 37781566google scholar: lookup
  72. Aleman M, Vedavally U, Pusterla N, Wensley F, Berryhill E, Madigan JE. Common and atypical presentations of Anaplasma phagocytophilum infection in equids with emphasis on neurologic and muscle disease.. J Vet Intern Med (2024) 38:440–8.
    doi: 10.1111/jvim.16964pmc: PMC10800209pubmed: 38038253google scholar: lookup
  73. Weiland G. Species-specific Serodiagnosis of equine piroplasma infections by means of complement fixation test (CFT), immunofluorescence (IIF), and enzyme-linked immunosorbent assay (ELISA).. Vet Parasitol (1986) 20:43–8.
    doi: 10.1016/0304-4017(86)90091-9pubmed: 3518216google scholar: lookup
  74. Vial HJ, Gorenflot A. Chemotherapy against Babesiosis.. Vet Parasitol (2006) 138:147–60.
    doi: 10.1016/j.vetpar.2006.01.048pubmed: 16504402google scholar: lookup
  75. Belloli C, Crescenzo G, Lai O, Carofiglio V, Marang O, Ormas P. Pharmacokinetics of imidocarb dipropionate in horses after intramuscular administration.. Equine Vet J (2002) 34:625–9.
    doi: 10.2746/042516402776180124pubmed: 12358005google scholar: lookup
  76. Abutarbush SM, Alfaqeeh SM, Mustafa G, Qura'n L, Al-Majali AM. Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.. Am J Vet Res (2013) 74:1404–8.
    doi: 10.2460/ajvr.74.11.1404pubmed: 24168305google scholar: lookup
  77. Kumar S, Gupta AK, Pal Y, Dwivedi SK. In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.. J Vet Med Sci (2003) 65:1171–7.
    doi: 10.1292/jvms.65.1171pubmed: 14665744google scholar: lookup
  78. Meyer C, Guthrie AJ, Stevens KB. Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate.. J S Afr Vet Assoc (2005) 76:26–32.
    doi: 10.4102/jsava.v76i1.390pubmed: 15900897google scholar: lookup
  79. Lewis BD, Penzhorn BL, Volkmann DH. Could treatment of pregnant mares prevent abortions due to equine piroplasmosis?. J S Afr Vet Assoc (1999) 70:90–1.
    doi: 10.4102/jsava.v70i2.760pubmed: 10855828google scholar: lookup
  80. Sears K, Knowles D, Dinkel K, Mshelia PW, Onzere C, Silva M. Imidocarb dipropionate lacks efficacy against Theileria haneyi and fails to consistently clear Theileria equi in horses co-infected with T. haneyi.. Pathogens (2020) 9:1035.
    doi: 10.3390/pathogens9121035pmc: PMC7764667pubmed: 33321715google scholar: lookup
  81. Onzere CK, Hulbert M, Sears KP, Williams LBA, Fry LM. Tulathromycin and diclazuril lack efficacy against Theileria haneyi, but tulathromycin is not associated with adverse clinical effects in six treated adult horses.. Pathogens (2023) 12:453.
    doi: 10.3390/pathogens12030453pmc: PMC10055745pubmed: 36986375google scholar: lookup
  82. Zaugg JL, Lane VM. Evaluations of buparvaquone as a treatment for equine babesiosis (Babesia equi).. Am J Vet Res (1989) 50:782–5.
    pubmed: 2729726
  83. Zaugg JL, Lane VM. Efficacy of buparvaquone as a therapeutic and clearing agent of Babesia equi of European origin in horses.. Am J Vet Res (1992) 53:1396–9.
    doi: 10.2460/ajvr.1992.53.08.1396pubmed: 1510317google scholar: lookup
  84. Müller J, Aguado-Martínez A, Manser V, Wong HN, Haynes RK, Hemphill A. Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical transmission in the pregnant neosporosis mouse model.. Vet Res (2016) 47:32.
    doi: 10.1186/s13567-016-0317-1pmc: PMC4756515pubmed: 26883424google scholar: lookup
  85. Bailey G. Buparvaquone tissue residue study.. North Sydney, Australia: Meat & Livestock Australia; (2013).
  86. Rashid HB, Chaudhry M, Rashid H, Pervez K, Khan MA, Mahmood AK. Comparative efficacy of diminazene diaceturate and diminazene aceturate for the treatment of Babesiosis in horses.. Trop Anim Health Prod (2008) 40:463–7.
    doi: 10.1007/s11250-007-9121-2pubmed: 18575975google scholar: lookup
  87. Huang L, Sun Y, Huo DD, Xu M, Xia LY, Yang N. Successful treatment with doxycycline monotherapy for human infection with Babesia venatorum (Babesiidae, Sporozoa) in China: a case report and proposal for a clinical regimen.. Infect Dis Poverty (2023) 12:67.
    doi: 10.1186/s40249-023-01111-1pmc: PMC10339522pubmed: 37443058google scholar: lookup
  88. Bork S, Yokoyama N, Matsuo T, Claveria FG, Fujisaki K, Igarashi I. Clotrimazole, ketoconazole, and clodinafop-propargyl as potent growth inhibitors of equine Babesia parasites during in vitro culture.. J Parasitol (2003) 89:604–6.
    doi: 10.1645/0022-3395(2003)089[0604:Ckacap]2.0.Co;2pubmed: 12880264google scholar: lookup
  89. Nagai A, Yokoyama N, Matsuo T, Bork S, Hirata H, Xuan X. Growth-inhibitory effects of artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia caballi in vitro cultures.. Antimicrob Agents Chemother (2003) 47:800–3.
    doi: 10.1128/aac.47.2.800-803.2003pmc: PMC151728pubmed: 12543697google scholar: lookup
  90. Donellan CM, Marais HJ. Equine piroplasmosis.. in Infectious diseases of the horse. Eds. Mair TS, Re H. (2009). Equine Veterinary Journal Ltd: UK, pp 333–340..
  91. Wise LN, Ueti MW, Kappmeyer LS, Hines MT, White SN, Davis W. In vitro activity of ponazuril against Theileria equi.. Vet Parasitol (2012) 185:282–5.
    doi: 10.1016/j.vetpar.2011.10.036pubmed: 22130334google scholar: lookup
  92. Tayebwa DS, Tuvshintulga B, Guswanto A, Nugraha AB, Batiha GE, Gantuya S. The effects of nitidine chloride and camptothecin on the growth of Babesia and Theileria parasites.. Ticks Tick Borne Dis (2018) 9:1192–201.
    doi: 10.1016/j.ttbdis.2018.04.019pubmed: 29730263google scholar: lookup
  93. Donnellan CMB, Page PC, Nurton JP, van den Berg JS, Guthrie AJ. Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses.. Equine Vet J (2013) 45:625–9.
    doi: 10.1111/evj.12032pubmed: 23461655google scholar: lookup
  94. Kutscha J, Sutton DGM, Preston T, Guthrie AJ. Equine piroplasmosis treatment protocols: specific effect on orocaecal transit time as measured by the lactose 13c-ureide breath test.. Equine Vet J (2012) 44:62–7.
    doi: 10.1111/j.2042-3306.2012.00656.xpubmed: 23447880google scholar: lookup
  95. Dodiya PG, Patel JS, Parmar VL, Kalariya VA, Singh VK. Clinical management of equine piroplasmosis.. Indian J Vet Sci Biotechnol (2022) 18:129–31.
    doi: 10.21887/ijvsbt.18.2.29google scholar: lookup
  96. Al-Mola G, Al-Saad K. Comparative study of imidocarb, buparvarvaquone & diminazinein treatment of draught horses affected with equine Babesiosis.. Iraqi J Vet Sci (2006) 20:103–12.
    doi: 10.33899/ijvs.2006.45788google scholar: lookup
  97. Butler CM, Nijhof AM, van der Kolk JH, de Haseth OB, Taoufik A, Jongejan F. Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization.. Vet Parasitol (2008) 151:320–2.
    doi: 10.1016/j.vetpar.2007.11.010pubmed: 18160222google scholar: lookup
  98. Mendoza FJ, Perez-Ecija A, Toribio RE. Clinical pharmacology in donkeys and mules.. Vet Clin North Am Equine Pract (2019) 35:589–606.
    doi: 10.1016/j.cveq.2019.08.011pubmed: 31587974google scholar: lookup
  99. Bartolome Del Pino LE, Meana A, Zini M, Cersini A. Evidence of transplacental transmission of equine piroplasms Theileria equi and Babesia caballi in an Italian breed mare.. Folia Parasitol (2023) 70:70.
    doi: 10.14411/fp.2023.005pubmed: 36960775google scholar: lookup
  100. Chhabra S, Ranjan R, Uppal SK, Singla LD. Transplacental transmission of Babesia equi (Theileria equi) from carrier mares to foals.. J Parasit Dis (2012) 36:31–3.
    doi: 10.1007/s12639-011-0072-1pmc: PMC3284609pubmed: 23543072google scholar: lookup
  101. Butler CM, van Gils JA, van der Kolk JH. A literature review of equine piroplasmosis after an episode of acute Babesiosis in a Dutch standardbred foal after a stay in Normandy.. Tijdschr Diergeneeskd (2005) 130:726–31.
    pubmed: 16363205
  102. Kumar S, Kumar R, Gupta AK, Dwivedi SK. Passive transfer of Theileria equi antibodies to neonate foals of immune tolerant mares.. Vet Parasitol (2008) 151:80–5.
    doi: 10.1016/j.vetpar.2007.10.001pubmed: 18022185google scholar: lookup
  103. Sant C, d'Abadie R, Pargass I, Basu AK, Asgarali Z, Charles RA. Prospective study investigating transplacental transmission of equine piroplasmosis in thoroughbred foals in Trinidad.. Vet Parasitol (2016) 226:132–7.
    doi: 10.1016/j.vetpar.2016.07.008pubmed: 27514898google scholar: lookup
  104. Hines SA, Ramsay JD, Kappmeyer LS, Lau AO, Ojo KK, Van Voorhis WC. Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.. Parasit Vectors (2015) 8:33.
    doi: 10.1186/s13071-014-0611-6pmc: PMC4311422pubmed: 25600252google scholar: lookup
  105. Chatanga E, Mosssad E, Abdo Abubaker H, Amin Alnour S, Katakura K, Nakao R. Evidence of multiple point mutations in Theileria annulata cytochrome b gene incriminated in buparvaquone treatment failure.. Acta Trop (2019) 191:128–32.
    doi: 10.1016/j.actatropica.2018.12.041pubmed: 30599177google scholar: lookup
  106. Bravo-Ramos JL, Sánchez-Montes S, Sánchez-Otero MG, Ballados-Gonzalez GG, Gamboa-Prieto J, Romero-Salas D. Molecular detection of Theileria cervi in equids from México.. Res Vet Sci (2023) 164:105017.
    doi: 10.1016/j.rvsc.2023.105017pubmed: 37696108google scholar: lookup
  107. Silva MG, Villarino NF, Knowles DP, Suarez CE. Assessment of Draxxin(®) (tulathromycin) as an inhibitor of in vitro growth of Babesia bovis, Babesia bigemina and Theileria equi.. Int J Parasitol Drugs Drug Resist (2018) 8:265–70.
    doi: 10.1016/j.ijpddr.2018.04.004pmc: PMC6039354pubmed: 29689532google scholar: lookup
  108. Mayence A, Vanden Eynde JJ. Tafenoquine: a 2018 novel FDA-approved prodrug for the radical cure of plasmodium vivax Nalaria and prophylaxis of malaria.. Pharmaceuticals (2019) 12:115.
    doi: 10.3390/ph12030115pmc: PMC6789594pubmed: 31366060google scholar: lookup
  109. Liu M, Ji S, Kondoh D, Galon EM, Li J, Tomihari M. Tafenoquine is a promising drug candidate for the treatment of Babesiosis.. Antimicrob Agents Chemother (2021) 65:e0020421.
    doi: 10.1128/aac.00204-21pmc: PMC8373227pubmed: 33941516google scholar: lookup
  110. Marcos LA, Leung A, Kirkman L, Wormser GP. Use of tafenoquine to treat a patient with relapsing Babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.. IDCases (2022) 27:e01460.
    doi: 10.1016/j.idcr.2022.e01460pmc: PMC8885462pubmed: 35242564google scholar: lookup
  111. Stone W, Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niambele SM. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.. Lancet Microbe (2022) 3:e336–47.
    doi: 10.1016/s2666-5247(21)00356-6pmc: PMC9042793pubmed: 35544095google scholar: lookup
  112. Vydyam P, Pal AC, Renard I, Chand M, Kumari V, Gennaro JC. Tafenoquine-atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human Babesiosis.. J Infect Dis (2024) 229:161–72.
    doi: 10.1093/infdis/jiad315pmc: PMC10786256pubmed: 38169301google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.